Cargando…
Activation pathway of a G protein-coupled receptor uncovers conformational intermediates as targets for allosteric drug design
G protein-coupled receptors (GPCRs) are the most common proteins targeted by approved drugs. A complete mechanistic elucidation of large-scale conformational transitions underlying the activation mechanisms of GPCRs is of critical importance for therapeutic drug development. Here, we apply a combine...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342441/ https://www.ncbi.nlm.nih.gov/pubmed/34354057 http://dx.doi.org/10.1038/s41467-021-25020-9 |
_version_ | 1783734071039361024 |
---|---|
author | Lu, Shaoyong He, Xinheng Yang, Zhao Chai, Zongtao Zhou, Shuhua Wang, Junyan Rehman, Ashfaq Ur Ni, Duan Pu, Jun Sun, Jinpeng Zhang, Jian |
author_facet | Lu, Shaoyong He, Xinheng Yang, Zhao Chai, Zongtao Zhou, Shuhua Wang, Junyan Rehman, Ashfaq Ur Ni, Duan Pu, Jun Sun, Jinpeng Zhang, Jian |
author_sort | Lu, Shaoyong |
collection | PubMed |
description | G protein-coupled receptors (GPCRs) are the most common proteins targeted by approved drugs. A complete mechanistic elucidation of large-scale conformational transitions underlying the activation mechanisms of GPCRs is of critical importance for therapeutic drug development. Here, we apply a combined computational and experimental framework integrating extensive molecular dynamics simulations, Markov state models, site-directed mutagenesis, and conformational biosensors to investigate the conformational landscape of the angiotensin II (AngII) type 1 receptor (AT(1) receptor) — a prototypical class A GPCR—activation. Our findings suggest a synergistic transition mechanism for AT(1) receptor activation. A key intermediate state is identified in the activation pathway, which possesses a cryptic binding site within the intracellular region of the receptor. Mutation of this cryptic site prevents activation of the downstream G protein signaling and β-arrestin-mediated pathways by the endogenous AngII octapeptide agonist, suggesting an allosteric regulatory mechanism. Together, these findings provide a deeper understanding of AT(1) receptor activation at an atomic level and suggest avenues for the design of allosteric AT(1) receptor modulators with a broad range of applications in GPCR biology, biophysics, and medicinal chemistry. |
format | Online Article Text |
id | pubmed-8342441 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-83424412021-08-20 Activation pathway of a G protein-coupled receptor uncovers conformational intermediates as targets for allosteric drug design Lu, Shaoyong He, Xinheng Yang, Zhao Chai, Zongtao Zhou, Shuhua Wang, Junyan Rehman, Ashfaq Ur Ni, Duan Pu, Jun Sun, Jinpeng Zhang, Jian Nat Commun Article G protein-coupled receptors (GPCRs) are the most common proteins targeted by approved drugs. A complete mechanistic elucidation of large-scale conformational transitions underlying the activation mechanisms of GPCRs is of critical importance for therapeutic drug development. Here, we apply a combined computational and experimental framework integrating extensive molecular dynamics simulations, Markov state models, site-directed mutagenesis, and conformational biosensors to investigate the conformational landscape of the angiotensin II (AngII) type 1 receptor (AT(1) receptor) — a prototypical class A GPCR—activation. Our findings suggest a synergistic transition mechanism for AT(1) receptor activation. A key intermediate state is identified in the activation pathway, which possesses a cryptic binding site within the intracellular region of the receptor. Mutation of this cryptic site prevents activation of the downstream G protein signaling and β-arrestin-mediated pathways by the endogenous AngII octapeptide agonist, suggesting an allosteric regulatory mechanism. Together, these findings provide a deeper understanding of AT(1) receptor activation at an atomic level and suggest avenues for the design of allosteric AT(1) receptor modulators with a broad range of applications in GPCR biology, biophysics, and medicinal chemistry. Nature Publishing Group UK 2021-08-05 /pmc/articles/PMC8342441/ /pubmed/34354057 http://dx.doi.org/10.1038/s41467-021-25020-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Lu, Shaoyong He, Xinheng Yang, Zhao Chai, Zongtao Zhou, Shuhua Wang, Junyan Rehman, Ashfaq Ur Ni, Duan Pu, Jun Sun, Jinpeng Zhang, Jian Activation pathway of a G protein-coupled receptor uncovers conformational intermediates as targets for allosteric drug design |
title | Activation pathway of a G protein-coupled receptor uncovers conformational intermediates as targets for allosteric drug design |
title_full | Activation pathway of a G protein-coupled receptor uncovers conformational intermediates as targets for allosteric drug design |
title_fullStr | Activation pathway of a G protein-coupled receptor uncovers conformational intermediates as targets for allosteric drug design |
title_full_unstemmed | Activation pathway of a G protein-coupled receptor uncovers conformational intermediates as targets for allosteric drug design |
title_short | Activation pathway of a G protein-coupled receptor uncovers conformational intermediates as targets for allosteric drug design |
title_sort | activation pathway of a g protein-coupled receptor uncovers conformational intermediates as targets for allosteric drug design |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342441/ https://www.ncbi.nlm.nih.gov/pubmed/34354057 http://dx.doi.org/10.1038/s41467-021-25020-9 |
work_keys_str_mv | AT lushaoyong activationpathwayofagproteincoupledreceptoruncoversconformationalintermediatesastargetsforallostericdrugdesign AT hexinheng activationpathwayofagproteincoupledreceptoruncoversconformationalintermediatesastargetsforallostericdrugdesign AT yangzhao activationpathwayofagproteincoupledreceptoruncoversconformationalintermediatesastargetsforallostericdrugdesign AT chaizongtao activationpathwayofagproteincoupledreceptoruncoversconformationalintermediatesastargetsforallostericdrugdesign AT zhoushuhua activationpathwayofagproteincoupledreceptoruncoversconformationalintermediatesastargetsforallostericdrugdesign AT wangjunyan activationpathwayofagproteincoupledreceptoruncoversconformationalintermediatesastargetsforallostericdrugdesign AT rehmanashfaqur activationpathwayofagproteincoupledreceptoruncoversconformationalintermediatesastargetsforallostericdrugdesign AT niduan activationpathwayofagproteincoupledreceptoruncoversconformationalintermediatesastargetsforallostericdrugdesign AT pujun activationpathwayofagproteincoupledreceptoruncoversconformationalintermediatesastargetsforallostericdrugdesign AT sunjinpeng activationpathwayofagproteincoupledreceptoruncoversconformationalintermediatesastargetsforallostericdrugdesign AT zhangjian activationpathwayofagproteincoupledreceptoruncoversconformationalintermediatesastargetsforallostericdrugdesign |